Astellas Wins OSI But Victory Comes At A Price
Executive Summary
Japanese drug maker Astellas' painstaking pursuit of OSI Pharmaceuticals was rewarded on May 17 with a definitive merger agreement that has the unanimous support of both companies' boards
You may also be interested in...
Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib
In a worldwide deal excluding Asia, the two companies will split both revenues and development costs 50/50 in North America and Europe.
Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib
In a worldwide deal excluding Asia, the two companies will split both revenues and development costs 50/50 in North America and Europe.
Sanofi/Genzyme Saga: War Before Peace?
Unless a white knight bidder emerges to thwart Sanofi-Aventis' attempt to acquire Genzyme, and soon, the Cambridge-Mass.-based biotech's best negotiating tactic may be stalling.